In humans, altered TGF-β1 levels have also been reported to be elevated in the CSF while reduced in the plasma of AD patients, which could serve both as a diagnostic marker and a potential target for neuroprotection [284]. This evidence concerns the gene TGFB1 and Alzheimer disease.